|
|
|
|
|
|
Sponsors and Collaborators: |
Abbott Genentech |
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00481091 |
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose.
The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.
Condition | Intervention | Phase |
Chronic Lymphocytic Leukemia |
Drug: ABT-263 |
Phase I Phase II |
MedlinePlus related topics: | Leukemia, Adult Acute Leukemia, Adult Chronic |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia |
Estimated Enrollment: | 72 |
Study Start Date: | July 2007 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm NA, Group is Applicable: Experimental
Group/Cohort Number or Label is numerical and sequential starting with dose level 1
|
Drug: ABT-263
Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Juliann Dziubinski | 847-7-5838 | juliann.dziubinski@abbott.com |
Contact: Melissa Kumar | 847-938-3885 | melissa.kumar@abbott.com |
United States, California | |||||
UCSD Moores Cancer Center | Recruiting | ||||
San Diego, California, United States, 92093 | |||||
Contact: Vineeta Prasad 858-822-0337 vprasad@ucsd.edu | |||||
Principal Investigator: Dr. Tom Kipps | |||||
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | Recruiting | ||||
Boston, Massachusetts, United States, 02115 | |||||
Contact: Lisa Gallegos 617-632-2368 lisak_gallegos@dfci.harvard.edu | |||||
Principal Investigator: Jennifer Brown, M.D. | |||||
United States, Texas | |||||
UT - MD Anderson Cancer Center | Recruiting | ||||
Houston, Texas, United States, 77230 | |||||
Contact: Blanche Anderson 713-563-9285 banderso@mda.org | |||||
Principal Investigator: William Wierda, M.D | |||||
Australia | |||||
Royal Melbourne Hospital | Recruiting | ||||
Victoria, Australia | |||||
Contact: Lisa Magee 61-3-9342-7905 lisa.magee@mh.org.au | |||||
Principal Investigator: Andrew Roberts, FRACP, PhD | |||||
Australia, Victoria | |||||
Peter MacCallum Cancer Center | Recruiting | ||||
East Melbourne, Victoria, Australia, 3002 | |||||
Contact: Kate Khamly 61-3-9656-1111 kate.khamly@petermac.org | |||||
Principal Investigator: John Seymour |
Abbott |
Genentech |
Study Director: | Sari Enschede, MD | Abbott |
Responsible Party: | Abbott ( Sari Enschede, M.D. ) |
Study ID Numbers: | M06-873 |
First Received: | May 30, 2007 |
Last Updated: | September 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00481091 |
Health Authority: | United States: Food and Drug Administration |
|
|
|